Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14364476 | 0.83 | CNR2 (0.34) | CNR2 | |
| SCHEMBL13949343 | 0.83 | CNR2 (0.34) | CNR2 | |
| SCHEMBL13949346 | 0.83 | CNR2 (0.34) | CNR2 | |
| SCHEMBL1786418 | 0.83 | CNR2 (0.34) | CNR2 | |
| SCHEMBL13949344 | 0.83 | CNR2 (0.34) | CNR2 | |
| SCHEMBL1786420 | 0.83 | CNR2 (0.34) | CNR2 | |
| SCHEMBL2210373 | 0.81 | CNR2 (0.30) | CNR2 | |
| SCHEMBL14603679 | 0.79 | — | — | |
| SCHEMBL3953711 | 0.75 | TRPA1 (0.34) | — | |
| SCHEMBL18257693 | 0.75 | ALOX15 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200140451-A1 | ENGLERIN DERIVATIVES FOR TREATMENT OF CANCER | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140451-A1 | ENGLERIN DERIVATIVES FOR TREATMENT OF CANCER | XPO5, ATP6V1B1, ENTPD5 | CNR2 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.